Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: results of the FFCD 0904 phase II trial.
Fiche publication
Date publication
juin 2023
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher, Pr LEPAGE Côme
Tous les auteurs :
Vendrely V, Ronchin P, Minsat M, Le Malicot K, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Darut-Jouve A, de la Fouchardière C, Giraud N, Breysacher G, Argo-Leignel D, Thimonnier E, Magné N, Ben Abdelghani M, Lepage C, Aparicio T,
Lien Pubmed
Résumé
Standard treatment of squamous cell carcinoma of the anus (SCCA)is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT). This phase II study (EudraCT: 2011-005436-26) assessed the tolerance and complete response (CR) rate at 8 weeks of panitumumab (Pmab) combined with MMC-5FU-based CRT.
Mots clés
Anal cancer, Chemoradiotherapy, Epidermal growth factor receptor, Immunotherapy, Panitumumab, Squamous cell carcinoma
Référence
Radiother Oncol. 2023 06 12;:109742